Close



Apr 16, 2024 07:00AM
Apr 8, 2024 07:08AM
Sep 10, 2023 05:15AM
Mar 2, 2023 04:28PM
Jan 26, 2023 05:51AM
Jan 26, 2023 02:00AM
Dec 19, 2022 05:15AM AstraZeneca (AZN) Announces ENHERTU Recommended for Approval in EU for HER2 Low Metastatic Breast Cancer
Dec 19, 2022 02:00AM
Dec 7, 2022 08:36AM
Oct 26, 2022 07:05AM
Oct 26, 2022 07:00AM
Aug 8, 2022 05:49AM
Aug 5, 2022 08:06PM
Aug 5, 2022 08:00PM ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
Aug 5, 2022 02:20PM
Aug 5, 2022 02:20PM
Jul 25, 2022 05:56AM
Jul 25, 2022 02:00AM
Jul 1, 2022 09:01AM
Jul 1, 2022 09:00AM
Jun 22, 2022 02:00AM Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease
Jun 14, 2022 04:08AM
Jun 6, 2022 05:53AM
Jun 5, 2022 08:10AM
Jun 5, 2022 08:00AM
Jun 4, 2022 10:00AM
Apr 27, 2022 07:00AM
Apr 27, 2022 05:49AM AstraZeneca (AZN) and Daiichi Sankyo Announce ENHERTU Granted Breakthrough Therapy Designation in US for Patients with HER2 Low Metastatic Breast Cancer
Apr 26, 2022 09:00PM
Mar 7, 2022 05:45AM
Mar 6, 2022 11:30PM
Feb 22, 2022 05:40AM
Feb 21, 2022 11:15AM
Feb 21, 2022 02:00AM
Jan 24, 2022 07:10AM AstraZeneca (AZN) announces Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
Jan 24, 2022 07:10AM
Jan 18, 2022 05:20PM
Dec 9, 2021 10:09AM
Nov 24, 2021 05:34AM
Nov 23, 2021 07:00PM
Oct 25, 2021 04:21PM
Sep 8, 2021 06:35AM HUTCHMED (HCM) and AstraZeneca (AZN) Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Aug 9, 2021 09:17AM
Jul 19, 2021 08:33AM
Jul 19, 2021 08:30AM
Dec 28, 2020 09:14AM
Sep 9, 2020 09:28AM
Sep 8, 2020 05:58PM
Jul 27, 2020 06:11AM Daiichi Sankyo and AstraZeneca (AZN) Enter Up to $6 Billion Pact for Daiichi Sankyo's ADC DS-1062
Sep 16, 2015 08:02AM

51,661 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All